Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
C-suite leaders race to keep up with the rapid pace of AI before competitors take the lead [Fortune]